Loading
A phase 2 trial of Paclitaxel / nab-paclitaxel in ovarian cancer, run by Shanghai Jiaolian Drug Research and Development Co., Ltd, now recruiting.
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT06434610 by Shanghai Jiaolian Drug Research and Development Co., Ltd, with 90 participants planned, started 2024-07-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: B013, Paclitaxel, Placebo. Conditions listed: Platinum-resistant Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/